Growth Metrics

Gyre Therapeutics (GYRE) Change in Receivables (2012 - 2026)

Gyre Therapeutics (GYRE) reported Change in Receivables of -$8.6 million for Q1 2026, down 1287.4% year-over-year from $722000.0 in Q1 2025, and down 277.68% on a QoQ basis from $4.8 million in Q4 2025.

Gyre Therapeutics (GYRE) has 13 years of Change in Receivables data on file, last reported at -$8.6 million in Q1 2026.

  • Quarterly Change in Receivables fell 1287.4% year-over-year to -$8.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.9 million (down 590.86% YoY) and the FY2025 annual result came in at $10.8 million, up 105.55% from the prior year.
  • Change in Receivables declined to -$8.6 million in Q1 2026 per GYRE's latest filing, from $4.8 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $4.8 million in Q4 2025 and bottomed at -$8.6 million in Q1 2026.
  • The 5-year median for Change in Receivables is -$564000.0 (2022), against an average of -$711857.1.
  • The widest annual swing landed in 2025, when Change in Receivables surged 321.03%; it then tumbled 1287.4% in 2026.
  • Tracing GYRE's Change in Receivables over 5 years: stood at -$564000.0 in 2022, then slumped by 163.3% to -$1.5 million in 2023, then jumped by 177.17% to $1.1 million in 2024, then soared by 321.03% to $4.8 million in 2025, then plunged by 277.68% to -$8.6 million in 2026.
  • Per Business Quant, the three latest GYRE Change in Receivables figures stand at -$8.6 million (Q1 2026), $4.8 million (Q4 2025), and $722000.0 (Q1 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 208,524.00
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -39.80 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -1.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 110.42 Mn
10 Gyre Therapeutics 532.38 Mn 518.25 Mn 8.38 Mn -8.57 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -8.57 Mn
Mar 31, 2026 -8.57 Mn
Dec 31, 2025 4.83 Mn
Dec 31, 2025 4.83 Mn
Mar 31, 2025 722,000.00
Mar 31, 2025 722,000.00
Dec 31, 2024 1.15 Mn
Dec 31, 2024 1.15 Mn
Dec 31, 2023 -1.49 Mn
Dec 31, 2023 -1.49 Mn
Jun 30, 2022 -564,000.00
Jun 30, 2022 -564,000.00
Mar 31, 2022 -1.05 Mn
Mar 31, 2022 -1.05 Mn
Dec 31, 2021 704,000.00
Dec 31, 2021 704,000.00
Sep 30, 2021 -857,000.00
Sep 30, 2021 -857,000.00
Jun 30, 2021 965,000.00
Jun 30, 2021 965,000.00
Mar 31, 2021 -2.31 Mn
Mar 31, 2021 -2.31 Mn
Dec 31, 2020 1.76 Mn
Dec 31, 2020 1.76 Mn
Sep 30, 2020 -433,000.00
Sep 30, 2020 -433,000.00
Jun 30, 2020 622,000.00
Jun 30, 2020 622,000.00
Mar 31, 2020 -13.63 Mn
Mar 31, 2020 -13.63 Mn
Dec 31, 2017 -27,000.00
Dec 31, 2017 -27,000.00
Sep 30, 2017 -83,000.00
Sep 30, 2017 -83,000.00
Jun 30, 2017 -93,000.00
Jun 30, 2017 -93,000.00
Mar 31, 2017 196,000.00
Mar 31, 2017 196,000.00
Dec 31, 2016 -70,000.00
Dec 31, 2016 -70,000.00
Sep 30, 2016 -361,000.00
Sep 30, 2016 -361,000.00
Jun 30, 2016 14,000.00
Jun 30, 2016 14,000.00
Mar 31, 2016 -44,000.00
Mar 31, 2016 -44,000.00
Dec 31, 2015 -156,000.00
Dec 31, 2015 -156,000.00
Sep 30, 2015 243,000.00
Sep 30, 2015 243,000.00
Jun 30, 2015 -295,000.00
Jun 30, 2015 -295,000.00
Mar 31, 2015 287,000.00
Mar 31, 2015 287,000.00
Dec 31, 2014 5,000.00
Dec 31, 2014 5,000.00
Sep 30, 2014 245,000.00
Sep 30, 2014 245,000.00
Jun 30, 2014 -315,000.00
Jun 30, 2014 -315,000.00
Mar 31, 2014 64,000.00
Mar 31, 2014 64,000.00
Dec 31, 2013 374,000.00
Dec 31, 2013 374,000.00
Sep 30, 2013 950,000.00
Sep 30, 2013 950,000.00
Jun 30, 2013 -275,000.00
Jun 30, 2013 -275,000.00
Mar 31, 2013 -997,000.00
Mar 31, 2013 -997,000.00
Dec 31, 2012 -1.17 Mn
Dec 31, 2012 -1.17 Mn